Вы искали: methodological (Датский - Английский)

strukturfonde) fællesskabsretten fællesskabsrettens abc family budgets - volume i - methodological handbook
fabrication of carbide and nitride pellets and the nitride irradiations niloc 1 and niloc 2 fact sheets on the european parliament and the activities of the european community family budgets

points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:
adjustment for baseline covariates

concept paper on the development of a cpmp points to consider on methodological issues in confirmatory clinical trials with flexible design and analysis plan.
concept paper on the development of a cpmp points to consider on methodological issues in confirmatory clinical trials with flexible design and analysis plan.

fællesskabsundersøgelse af frugtplantager 1987 family budgets ­ volume i ­ methodological handbook family policy in eec countries farm accountancy data network: an a to Ζ of methodology
family budgets ­ volume i ­ methodological handbook family policy in eec countries farm accountancy data network: an a to Ζ of methodology farms in mountainous and less­favoured areas of the

adjustment for multiplicity and related topics points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:
adjustment for multiplicity and related topics points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:

choice of non- inferiority margin points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:
2) – addendum on paediatric oncology

de relevante undersøgelser skal gennemføres efter internationalt validerede testmetoder og i overensstemmelse med gældende ef-retsforskrifter eller oecd's guidelines for methodological details og med principperne for god laboratoriepraksis.
studies must be carried out using internationally validated test methods and shall be performed in accordance with european legislation in force or oecd guidelines for methodological details and according to the principles of glp.

side 41/59points to consider on biostatistical/methodological issues arising from cpmp discussion on licensing applications:choice of non-inferiority margin points to consider on biostatistical/methodological issues arising from cpmp discussion on licensing applications:adjustment for baseline covariates points to consider on the use of statistical methods for flexible design and analysis of confirmatory clinical trials points to consider on clinical pharmacokinetic investigation of the pharmacokinetics of peptides and proteins note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function points to consider on the evaluation of the pharmacokinetics of medicinal products in the paediatric population note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with hepatic impairment note for guidance on clinical investigation of medicinal products for the treatment of psoriasis points to consider on allergic rhino-conjuctivitis addendum to the note for guidance on modified release oral and transdermal dosage forms:
note for guidance on the evaluation of medicinal products forthe treatment of dyslipoproteinaemianote for guidance on clinical investigation of steroid contraceptives in women revision of note for guidance on evaluation of new anti-bacterial medicinal products (cpmp/ewp/558/95) and note for guidance on the pharmacodynamic section of the summary of product characteristics for antibacterial medicinal productspoints to consider on biostatistical/methodological issues arisingfrom cpmp discussion on licensing applications:choice of non-inferiority marginpoints to consider on biostatistical/methodological issues arising from cpmp discussion on licensing applications:adjustment forbaseline covariatespoints to consider on the use of statistical methods for flexibledesign and analysis of confirmatory clinical trialspoints to consider on clinical pharmacokinetic investigation of the pharmacokinetics of peptides and proteinsnote for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal functionpoints to consider on the evaluation of the pharmacokinetics of medicinal products in the paediatric population note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with hepatic impairment note for guidance on clinical investigation of medicinal products for the treatment of psoriasis points to consider on allergic rhino-conjuctivitis addendum to the note for guidance on modified release oral and transdermal dosage forms: